CryoCath CE-marks second cardiac ablation catheter:
This article was originally published in Clinica
CryoCath Technologies has gained the go-ahead to sell its second cardiac ablation catheter in Europe. The Freezor Xtra device can create lesions that are significantly larger than those of the firm's original Freezor catheter, allowing surgeons to treat arrhythmias further from the AV node that require more robust lesions - such as atrial fibrillation, and ventricular tacchycardia. The Kirkland, Quebec firm plans to file for US approval for the original Freezor device in the autumn of next year. It forecasts that US approval for the Xtra catheter could come in 2004.